Welcome to our dedicated page for Vireo Growth news (Ticker: VREOF), a resource for investors and traders seeking the latest updates and insights on Vireo Growth stock.
Vireo Growth Inc. (VREOF) generates a steady flow of news driven by its activities in the cannabis industry, including medical and adult-use operations, multi-state expansion, and corporate transactions. As a company that describes itself as a pioneering medical cannabis operator founded in 2014, Vireo uses press releases to communicate developments in its retail footprint, cultivation and production capacity, and strategic initiatives.
Recent news items highlight several key themes. One is geographic expansion and market entry. Vireo announced an Agreement and Plan of Merger to acquire Eaze Inc., a vertically integrated cannabis retailer and delivery technology platform with operations in California, Florida, and Colorado. The company states that this transaction is intended to mark its entry into California and Florida and to strengthen its position in Colorado, with Eaze becoming a wholly owned subsidiary upon closing.
Another recurring theme is M&A and capital structure activity. Vireo has reported entering into agreements to acquire a majority of Schwazze’s senior secured convertible notes, participating in a restructuring support agreement that contemplates an asset sale to a new entity to be majority-owned by Vireo, and negotiating an Asset Purchase Agreement to acquire Colorado dispensary assets from PharmaCann Inc. These announcements detail transaction terms, consideration in subordinate voting shares, and conditions such as regulatory approvals.
Operational updates also feature prominently. Vireo issued a release announcing the launch of adult-use cannabis sales in Minnesota at its Green Goods dispensaries, noting that it dispenses both medical and adult-use products at eight locations in the state. Quarterly earnings releases provide summaries of financial performance, state-by-state revenue, and non-GAAP metrics, accompanied by management commentary on integration of acquisitions and portfolio development.
Investors and observers who follow VREOF news can use this stream of announcements to monitor transaction progress, regulatory milestones, market entries, adult-use launches, litigation resolutions, and financial reporting updates, all of which are documented through Globe Newswire releases and linked SEC filings.
Vireo Growth (OTCQX:VREOF) has announced the retirement of its US$10 million convertible note that was due November 1, 2024. The company has simultaneously issued a new US$10 million convertible note on July 7, 2025, as part of a larger refinancing initiative.
The transaction is classified as a "related party transaction" under MI 61-101, as the lender is considered a related party to Vireo. However, the transaction is exempt from formal valuation and minority shareholder approval requirements since the value does not exceed 25% of Vireo's market capitalization.
Vireo Growth (OTCQX:VREOF) has successfully completed a major debt refinancing and expansion of its credit facilities. The company secured a $120 million self-syndicated first lien term loan at 8.3% interest rate and a $33 million second lien term loan with a $50 million accordion feature.
The total $153 million financing package is expected to generate over $10 million in annual interest savings and provides the company with more than $100 million in cash. The refinancing consolidates debt assumed from recent mergers and optimizes the company's capital structure. Both facilities have three-year terms and can be prepaid without penalties.
Vireo Growth Inc. (OTCQX: VREOF) has announced a strategic licensing partnership with Curio Wellness to manufacture and distribute Curio's Best Self Collection products in New York's cannabis market. The agreement enables Vireo to produce and distribute Curio's complete product portfolio, including topicals, tablets, chews, and vapes, using Vireo's existing New York infrastructure.
This capital-efficient growth strategy allows Curio to enter the New York market without significant investment, while Vireo expands its portfolio with Curio's GMP-certified, nationally recognized products. The partnership leverages Vireo's established presence in New York and Curio's reputation for quality and consistency in health and wellness cannabis products.
The companies expect to launch Curio-branded products in New York dispensaries in Q4 2025.
Vireo Growth Inc. (VREOF) has successfully closed two strategic acquisitions: WholesomeCo Cannabis, a dominant player in Utah's medical market, and the Arches proprietary technology platform for a total of $69.8 million. The deal was executed through 134.2 million Subordinate Voting Shares at $0.52 per share.
The Wholesome acquisition, valued at 4.175x its 2024 Reference EBITDA of $16 million, includes clawback provisions tied to performance milestones through December 2026. Shareholders agreed to a 33-month lock-up period. The company also expects to close pending mergers in Missouri and Nevada in Q2 2025.
Vireo Growth has scheduled the release of its first quarter 2025 financial results for May 9, 2025, before market opening. The cannabis company, trading under symbols CSE: VREO and OTCQX: VREOF, will follow the release with an investor conference call at 8:30 a.m. ET (7:30 a.m. CT).
Stakeholders can participate in the conference call through multiple channels:
- US/Canada Toll-Free: 1-888-672-2415
- International Toll: 1-646-307-1963
- Conference ID: 3718174
Additionally, interested parties can access a live audio webcast through the Events & Presentations section of Vireo's Investor Relations website or via the provided Q4 link.
Vireo Growth (CSE: VREO; OTCQX: VREOF) has announced key updates regarding its previously-announced Merger Transactions, expected to close in Q2 2025. The company has filed its Definitive Information Circular on March 21, 2025, which includes proforma financial information for the combined company and audited financial data for 2023-2024 for all merger targets.
The company has secured required shareholder approval through written consent for the Merger Transactions and the issuance of Subordinate Voting Shares (SV Shares) as consideration. The issuance is significant as it will exceed 100% of the company's total outstanding voting equity shares.
Regulatory approvals have been obtained for the Utah transactions, including Wholesome Cannabis and the Arches technology platform. The Missouri and Nevada transactions are progressing as planned for Q2 2025 closure, pending CSE approval and satisfaction of customary closing conditions.